Most Read Articles
5 days ago
Supplementation with probiotics may have positive effects in patients with type 2 diabetes mellitus (T2DM), reports a recent meta-analysis.
5 days ago
Ensituximab, a chimeric monoclonal antibody targeting a variant of MUC5AC, shows modest clinical activity with good safety profile in patients with refractory colorectal cancer, according to data from a phase II study.
Roshini Claire Anthony, 30 Jul 2020

Frailty may indicate an increased risk of death from COVID-19, results of the COPE* study showed.

3 days ago
Treatment with tradipitant in patients with idiopathic or diabetic gastroparesis produces meaningful improvements in nausea and vomiting, according to the results of a phase II trial.

Pharmacist presence in clinic reduces polypharmacy in multiple myeloma patients

05 May 2020
When is enough really enough for patients in light of the growing shift towards polypharmacy?

The rate of polypharmacy is high among patients with multiple myeloma, according to a study. However, comanagement with a pharmacist reduces the number of all medications, particularly those that are not related to myeloma.

A retrospective chart review was performed in an urban academic cancer centre using electronic records of 44 patients in the traditional physician-managed clinic and 57 patients in the collaborative physician-pharmacist clinic.

On average, patients in the collaborative clinic used fewer medications (9 vs 7; p=0.045). The median number of medications for the treatment of myeloma was higher (2 vs 4; p<0.001), but the number of nonmyeloma-related medications was lower (7 vs 3; p<0.0001) in the collaborative clinic.

Although both clinics demonstrated high rates of polypharmacy (93 percent vs 84 percent; p=0.22), the collaborative clinic had a substantially lower rate of polypharmacy of nonmyeloma medications (71 percent vs 33 percent; p=0.0003), including both minor (five to nine medications: 48 percent vs 28 percent; p=0.06) and major (≥10 medications: 23 percent vs 5 percent; p=0.02) polypharmacy.

On the other hand, patients in the collaborative clinic had significantly higher minor polypharmacy of myeloma-related medications (32 percent vs 2 percent; p=0.0002).

In multivariate analysis, patients in the collaborative clinic had a reduced risk of having a higher number of medications (relative risk [RR], 0.79, 95 percent confidence interval [CI], 0.67–0.93; p=0.004), a lower risk of having any polypharmacy of nonmyeloma-related medications (RR, 0.41, 95 percent CI, 0.25–0.67; p<0.001) and a lower risk of receiving potentially inappropriate medication (RR, 0.62, 95 percent CI, 0.41–0.95; p=0.029).

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Doctor - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
5 days ago
Supplementation with probiotics may have positive effects in patients with type 2 diabetes mellitus (T2DM), reports a recent meta-analysis.
5 days ago
Ensituximab, a chimeric monoclonal antibody targeting a variant of MUC5AC, shows modest clinical activity with good safety profile in patients with refractory colorectal cancer, according to data from a phase II study.
Roshini Claire Anthony, 30 Jul 2020

Frailty may indicate an increased risk of death from COVID-19, results of the COPE* study showed.

3 days ago
Treatment with tradipitant in patients with idiopathic or diabetic gastroparesis produces meaningful improvements in nausea and vomiting, according to the results of a phase II trial.